Name | M435-1279 |
Description | M435-1279 is a UBE2T inhibitor that blocks UBE2T-mediated degradation of RACK1, thereby inhibiting the hyperactivation of the Wnt/β-catenin signaling pathway. |
In vitro | M435-1279 (0, 2, 4, 8, 16, 31 μM; 48 h) significantly inhibits the growth of AGS, HGC27, and MKN45 cells. It also inhibits cell viability with IC50s of 16.8, 11.88, 7.76, and 6.93 μM for GES-1, HGC27, AGS, and MKN45 cells, respectively. M435-1279 (31 nM to 500 μM) binds to UBE2T protein with a KD value of 50.5 μM and (11.88 μM; 48 h) blocks the ubiquitination of RACK1, thereby inhibiting the hyperactivation of the Wnt/β-catenin pathway[1]. |
In vivo | M435-1279 (5 mg/kg/day; intratumor injection; 18 days) inhibits tumor growth and induces increased expression of RACK1 proteins while decreasing expression of Ki-67 and β-catenin proteins in intratumor tumors[1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 45.0 mg/mL (107.3 mM), Sonication is recommended.
|
Keywords | M435-1279 | M435 1279 | M4351279 |
Inhibitors Related | NSC697923 | PYZD-4409 | Nutlin-3 | NAcM-OPT | RG7112 | PYR-41 | BC-1382 | NSC232003 | NAE-IN-M22 | Indole-3-carbinol | Idasanutlin | Navtemadlin |
Related Compound Libraries | Bioactive Compound Library | Inhibitor Library | Bioactive Compounds Library Max |